

## Japan Innovation Night Participant – Startup Pitch Session –

No.	Japanese HQ Company Name	HQ Location	Technology Area	Company Business Summary	Website
1	Axcelead Drug Discovery Partners, Inc.	Kanagawa Japan	Drug Discovery	Axcelead Drug Discovery Partners Inc. is the first solution provider of integrated drug discovery in Japanese pharmaceutical industry. Experienced drug discovery researchers will promote drug discovery research together with customers and contribute to creation of innovative drugs by making full use of the drug discovery platform and knowledge inherited from Takeda Pharmaceutical Company, Ltd., and incorporating the brand-new science and technology.	<a href="https://www.axcelead.com/en/">https://www.axcelead.com/en/</a>
2	EditForce, Inc.	Fukuoka Japan	Gene Therapy/ RNA Editing	We strive to discover and develop gene therapy drugs based on our PPR Platform, mainly in CNS, muscular, and rare diseases. Our lead program EF-210 established in-vivo POC on Myotonic Dystrophy Type 1, and we are looking for a partner to bring EF-210 to clinical/commercial stage. We are also open to collaborate for drug discovery project using our PPR Platform.	<a href="https://www.editforce.co.jp/en/">https://www.editforce.co.jp/en/</a>
3	FELIQS CORPORATION	Fukuoka Japan	Therapeutics	FELIQS raised 2.5 M USD in 2022 to conduct pre-IND meeting with FDA and manufacture the investigational drug (FLQ-101). FLQ-101 is expected to initiate the clinical trial for retinopathy of prematurity in the US in 2024. FLQ-104, a new chemical entity, will be developed for dry age-related macular degeneration. The team consists of pharma experts with advisors who are world-class experts in ophthalmology research and drug discovery R&D.	<a href="https://www.feliqs.com/home">https://www.feliqs.com/home</a>
4	FunPep Co., Ltd.	Osaka Japan	Drug development (Peptide therapeutic vaccine)	FunPep is a public, clinical-stage therapeutics company that has developed antibody-inducing peptide platform. Our lead asset is licensed to Shionogi, with another clinical asset optioned to Sumitomo Pharma, and two ongoing R&D collaborations. We are seeking to partner our three pre-clinical assets and find additional R&D collaborations for our platform.	<a href="https://www.funpep.co.jp/en/">https://www.funpep.co.jp/en/</a>
5	J-Pharma Co., Ltd.	Kanagawa Japan	Biotech	J-Pharma was founded in 2005 and has been focusing on drug development targeting SLC transporters. Based on our achievements including the clinical study success and alliance, we have met the requirements for IPO in Japan and plan to go public around the end of next year for accelerate our clinical development.	<a href="https://www.j-pharma.com/en/">https://www.j-pharma.com/en/</a>
6	MiCAN Technologies, Inc.	Kyoto Japan	Produces and sales research reagents	Our products are high precision immature blood cells. We provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drugs and functional materials, as well as the research of infectious diseases. We also provide evaluation kits and offer various contract evaluation services, please feel free to contact us.	<a href="https://www.mican-technologies.com/">https://www.mican-technologies.com/</a>
7	NB HEALTH LABORATORY CO., LTD	Hokkaido Japan	Drug discovery	We are considering two monetization schemes. First prior to manufacturing step the internal pipelines will be out-licensed to pharmaceutical companies. Second, NBHL will conduct manufacturing and Phase study to confirm POC in human for particular pipelines by ourselves. After obtaining POC data in human, we will out-license the pipeline.	<a href="https://nbhl.co.jp/">https://nbhl.co.jp/</a>
8	PURMX Therapeutics, Inc.	Hiroshima Japan	MicroRNA Medicine	In a Phase I clinical trial, we are evaluating our lead product, MIRX002 for malignant pleural mesothelioma. We expect to have results of Phase 1 study at the end of 2023. We have also confirmed the non-clinical efficacy of the other pipelines.	<a href="https://www.purmx.com/en">https://www.purmx.com/en</a>
9	Rebirthel Co., Ltd.	Kyoto Japan	Immunotherapy, Cell therapy	Rebirthel's aim is providing novel treatments against cancer, infectious diseases, and other immune-related maladies. Our strategy is based upon the technology of killer T cell regeneration from PSCs, which was pioneered by Professor Hiroshi Kawamoto, Kyoto University. Our business consists of two components: i) in-house research, where we promote our proprietary R&D and ii) licensing, where we license our specialized technologies to other firms which are using patient-derived adoptive immunotherapy.	<a href="https://rebirthel.com/en/">https://rebirthel.com/en/</a>
10	RegCell Co., Ltd.	Osaka Japan	Cell therapy; Regulatory T cell; Regenerative Medicine; Precision Medicine	RegCell was founded by a discoverer of regulatory T cells (Tregs) to provide one-shot cure for autoimmune diseases. RegCell is developing pipelines & actively collaborating on the development of next-gen Tregs. Lead pipeline "Reg-PD101" has demonstrated antigen-specific immunomodulatory effects in multiple models. Reg-PD101 will enter a clinical trial from 2024.	<a href="https://regcell.jp/en/">https://regcell.jp/en/</a>
11	VC Cell Therapy	Hyogo Japan	Ophthalmology, Regenerative Medicine	VC Cell Therapy inc., develops cell therapy products for regenerative medicine in ophthalmology, specifically to treat patients suffering from impaired vision from age-related macular degeneration or retinitis pigmentosa. The company is at clinical stage, and planning to execute development, manufacturing and sales in Japan with partners. For global development, VCCT will license out assets to pharmaceutical partners. The company is led by Masayo Takahashi, a Nature's top 10 scientists 2014.	<a href="https://www.vect.jp/english">https://www.vect.jp/english</a>